Editas Medicine (EDIT) vs SAB Biotherapeutics (SABS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
SAB Biotherapeutics (SABS) has outperformed Editas Medicine (EDIT) over the past year, losing 28.9% versus a loss of 32.2%. Over five years, EDIT leads with a -94.9% price change compared with -97.3% for SABS. SAB Biotherapeutics is the larger company by market cap ($253.1 million vs $253.1 million), about 1.0 times the size, while Editas Medicine is growing revenue faster (+25.4% vs -100.0%).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | EDIT | SABS |
|---|---|---|
| Share price | $1.64 | $2.81 |
| Market cap | $253.12M | $253.15M |
| 1-day change | -4.09% | -3.44% |
| YTD return | -20.00% | -24.87% |
| 1-year return | -32.23% | -28.86% |
| 5-year return | -94.93% | -97.32% |
| EPS (TTM) | $-0.54 | $-1.35 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $40.52M | $0 |
| Revenue growth (YoY) | +25.39% | -100.00% |
| Net income (latest FY) | $-160.06M | $13.27M |
| Operating margin | -394.89% | — |
| Net margin | -395.01% | — |
| 52-week high | $3.94 | $5.15 |
| 52-week low | $1.63 | $2.44 |
| Distance from 52-week high | -58.38% | -45.44% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +271.95% | +314.23% |
| Average volume | 2.63M | 633.60K |
| Shares outstanding | 154.34M | 90.09M |
| Employees | 87 | 86 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Editas Medicine grew revenue faster in its latest fiscal year (+25.39% vs -100.00%).
About Editas Medicine
EDIT stock →Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 87 employees
About SAB Biotherapeutics
SABS stock →SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candidate is SAB-142, a potentially disease-modifying and redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes in Phase 2b clinical trials.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 86 employees
EDIT vs SABS FAQ
Which is bigger, Editas Medicine or SAB Biotherapeutics?
SAB Biotherapeutics (SABS) is larger, with a market capitalization of $253.15M compared with $253.12M for Editas Medicine (EDIT).
Which stock has performed better over the past year, EDIT or SABS?
SABS returned -28.86% over the past 12 months, compared with -32.23% for EDIT (price return, excluding dividends). Past performance does not predict future results.
Are Editas Medicine and SAB Biotherapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.